NEXGEL, Inc. (NXGLW) Stock Price & Analysis
NEXGEL, Inc. (NXGLW) — price $0.0098 (+13.95%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
NEXGEL, Inc. · NXGLW
NEXGEL, Inc. specializes in manufacturing and selling hydrogels for various applications, including wound care and cosmetics. The company operates through its Nexgel and CG labs segments, focusing on over-the-counter remedies and developing advanced medical products.
Price as of Nov 19, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0098 | |
| Change on the day | +13.95% | |
| 52-week range | $0.005 – $0.314 | |
| Shares traded on the day | 7.5K |
Price & events
What is NEXGEL (NXGLW), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. NEXGEL, Inc. (NXGLW) is the company analyzed here. It employs 19 people and is led by Brian J. Kieser. In Q2 FY2026 it reported revenue of $4M and net income of -$4M.
What do the latest results show for NEXGEL (NXGLW)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $4M. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $4M | -$4M | -$8.07 (diluted) |
| Q1 FY2026 | $3M | -$927,000 | -$2.26 (diluted) |
| Q4 FY2025 | $3M | -$970,000 | -$2.41 (diluted) |
| Q3 FY2025 | $3M | -$653,000 | -$1.64 (diluted) |
What are the financial strengths and risks for NEXGEL (NXGLW)?
Short answer · as of
The distress and quality screens read Altman Z -1.83 · Piotroski F 2. Trailing ratios: ROA -23.4% · current ratio 0.43.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -1.83 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NXGLW in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported NXGLW in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About NXGLW
These answers are editorial: 1 of these 1 answer is drawn from the NXGLW research dossier (written Mar 16, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What does NEXGEL, Inc. do?
NEXGEL, Inc. specializes in the development, manufacturing, and sale of high water content hydrogels. These hydrogels are used in a variety of applications, including wound care, medical diagnostics, transdermal drug delivery, and cosmetics.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 7 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com